Trelegy Ellipta on Medicare in 2026: Coverage, the $2,100 Cap, and Patient Assistance

Trelegy Ellipta is a once-daily 3-in-1 inhaler: a triple therapy that combines three COPD maintenance medicines in a single device. For most people on Medicare, what Trelegy costs comes down to four things: whether their Medicare Part D plan lists it on the formulary, the new 2026 out-of-pocket cap, whether they qualify for Extra Help, and whether GSK's patient assistance program applies to them.

Copay assistance works very differently on Medicare than on private insurance, and the rules for 2027 are already changing. This guide walks through each option in the order most people should check them.

The short version: a manufacturer copay card is usually not an option once you are on Medicare, but several Medicare-specific routes can cut the cost substantially, and open enrollment (October 15 to December 7) is the window to act on most of them.

Does Medicare cover Trelegy?

Original Medicare (Parts A and B) does not cover inhalers you pick up at a pharmacy. Trelegy is covered through Part D, either as a stand-alone drug plan or as part of a Medicare Advantage plan with drug coverage. Many Part D plans include it, but not all do, and plans place it on different cost tiers. Some also require prior authorization or step therapy, meaning your prescriber may need to show that a dual inhaler was tried first.

Because Trelegy is a brand-name drug with no generic version, the tier your plan assigns it to drives most of what you pay before the annual cap kicks in. If you are comparing plans this fall, enter Trelegy and your pharmacy into Medicare's Plan Finder rather than relying on a plan's general description. For a broader look at how plans treat COPD maintenance inhalers, see our guide to COPD inhalers covered by Medicare.

The 2026 Part D out-of-pocket cap: $2,100

Since 2025, Medicare Part D has had a hard ceiling on what you pay for covered drugs in a calendar year. For 2026 that ceiling is $2,100. It counts your deductible (up to $615 in 2026), copays and coinsurance. It does not count your monthly premium. Once your out-of-pocket spending on covered drugs reaches $2,100, you pay nothing more for covered Part D drugs for the rest of the year.

For someone using a brand-name triple-therapy inhaler every month, that cap matters a great deal: it turns an open-ended cost into a known maximum. Two practical points follow from it.

The cap only applies if Trelegy is on your plan's formulary. A drug your plan doesn't cover doesn't count toward it, which is why checking formularies during open enrollment matters more than ever.
You can spread the cost out. The Medicare Prescription Payment Plan lets you pay your out-of-pocket drug costs in monthly installments instead of all at once early in the year. It isn't income-based, but you have to sign up through your plan.

For a cost breakdown of the most common COPD inhalers under these rules, see our 2026 cost guide to Medicare coverage for COPD inhalers.

Extra Help: the biggest discount most people never apply for

Extra Help, also called the Low-Income Subsidy, is a federal program that lowers Part D premiums, deductibles and copays. In 2026, people with Extra Help pay no Part D deductible, and copays on brand-name drugs like Trelegy are capped at a few dollars per fill: up to $4.90 for those with incomes at or below the federal poverty level, and up to $12.65 for those above it who still qualify.

Many people qualify automatically through Medicaid or a Medicare Savings Program. Others have to apply through Social Security. For 2026, the resource limits are $18,090 for an individual and $36,100 for a married couple, and income limits apply as well. Because the copay difference on a brand-name inhaler is so large, it is worth applying even if you think you are close to the limit.

GSK's patient assistance program on Medicare

GSK, the maker of Trelegy, runs a patient assistance program that can provide medicines at no cost to people who meet its requirements. Unlike GSK's commercial savings card, it has a specific pathway for people with Medicare Part D. Under that pathway, applicants generally need to:

have a Medicare Part D prescription drug plan;
meet the program's household income limits; and
show, with their most recent Part D Explanation of Benefits, that they have already spent $600 on prescriptions in the current calendar year.

The application is submitted with a copy of your Part D card, the Explanation of Benefits and your prescription, and people on Medicare must reapply each calendar year. Because of the $600 threshold, many people apply partway through the year rather than in January.

Why the copay card usually doesn't work

Manufacturer copay and savings cards are designed for people with commercial insurance. Federal rules generally bar their use with Medicare, Medicaid and other government coverage, so a Trelegy savings card will normally be declined if you are on Part D. Pharmacy discount cards are a separate thing: they can sometimes lower the cash price, but purchases made with them usually do not count toward your Part D deductible or the $2,100 cap.

What changes in 2027

Trelegy Ellipta was one of 15 drugs selected for the second round of Medicare drug price negotiation. CMS announced the negotiated prices in November 2025, and they take effect on January 1, 2027. Lower negotiated prices are expected to reduce what Part D enrollees pay for the selected drugs, though the exact effect on any one person depends on their plan's design and how far they are from the annual cap.

If you are choosing a plan during this fall's open enrollment, you are choosing it for 2027, so this change is already relevant.

Talking to your prescriber about alternatives

Trelegy is one of two widely prescribed triple-therapy inhalers for COPD, and there are several dual-combination inhalers as well. If your plan covers a different inhaler on a lower tier, it can be worth asking your prescriber whether it would be a reasonable fit. That is a medical decision, and switching without guidance can affect symptom control. COPD care also extends well beyond inhalers; our chronic lung disease management guide covers the rest of a typical plan, and for complex cases our list of leading lung hospitals may help.

If you have also seen newer federal pricing programs mentioned for inhalers, our 2026 inhaler coverage guide explains how they relate to Part D.

A simple order of operations

During open enrollment (Oct 15 to Dec 7): check whether Trelegy is on your current plan's 2027 formulary, and at what tier. Compare plans with Trelegy entered.
Check Extra Help eligibility. If you qualify, it lowers your costs more than any other single step.
Know your cap. If your plan covers Trelegy, your covered-drug spending can't exceed $2,100 in 2026. Consider the payment plan if a large early-year bill is the problem.
Track your spending. Once you have spent $600 on prescriptions in the year, review whether you meet GSK's patient assistance income limits.
Ask about alternatives only with your prescriber, and only if cost is still a barrier after the steps above.

Costs and eligibility rules change every year, and individual plans vary. Confirm the details with your plan, Medicare, Social Security, or the manufacturer's program before making a decision.